US Biomarkers, Inc.

...is a discovery-driven early-stage company with a proprietary platform for development of blood-based biomarkers using disease-specific epigenetic changes

Learn More »

Blood-based Biomarkers for Early Diagnosis and Prediction of Drug Efficacy in Cancer & Multiple Sclerosis


US Biomarkers, Inc is a discovery-driven formation-stage company with a proprietary platform for development of blood-based biomarkers using disease-specific epigenetic changes.

We develop blood-based diagnostic tools for early detection of different diseases, when the chances of cure are the highest.

In collaboration with pharmaceutical partners, US Biomarkers, Inc will develop blood-based tests for disease management.

Our goal is a simple, fast, inexpensive and accurate test for disease diagnosis and monitoring.

The Mission


Our mission is to develop and validate clinically useful biomarkers for...


News



Dr. Levenson will be presenting at

"Methylation of cell-free circulating DNA in blood: development and validation of biomarkers for pancreatic cancer.
GTCBio Fourth Oncology Biomarker conference (March 15-16, 2012 in San Diego, CA)

"Methylation patterns in cell-free circulating DNA from blood for detection and diagnosis of disease.
SelectBiosciences Genomics Research 2012 (April 19-20, 2012, Boston, MA)

Validation of blood-based DNA methylation biomarkers for pancreatic cancer and chronic pancreatitis.
Canary Symposium on Early Detection (May 1-2, 2012, Stanford, CA)